Found: 17
Select item for more details and to access through your institution.
Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies-bendamustine and G-CSF support.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Safety and comfort of domestic bortezomib injection in real-life experience.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone.
- Published in:
- 2016
- By:
- Publication type:
- Letter
Rituximab in a risk‐adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte‐predominant Hodgkin lymphoma.
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide.
- Published in:
- Clinical Case Reports, 2017, v. 5, n. 4, p. 505, doi. 10.1002/ccr3.773
- By:
- Publication type:
- Article
Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pretreated Multiple Myeloma: Old/New in Novel Agents' Era.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e359, doi. 10.1016/j.clml.2019.09.594
- By:
- Publication type:
- Article
Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e359, doi. 10.1016/j.clml.2019.09.593
- By:
- Publication type:
- Article
Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e358, doi. 10.1016/j.clml.2019.09.592
- By:
- Publication type:
- Article
Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment With Pomalidomide-Dexamethasone.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e358, doi. 10.1016/j.clml.2019.09.591
- By:
- Publication type:
- Article
Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S256, doi. 10.1016/j.clml.2018.07.161
- By:
- Publication type:
- Article
Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S255, doi. 10.1016/j.clml.2018.07.159
- By:
- Publication type:
- Article
Full Standard Doses of Lenalidomide in Bortezomib-Refractory Multiple Myeloma Patients Affected by Renal Failure: A Real-Life Experience.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S342, doi. 10.1016/j.clml.2017.07.162
- By:
- Publication type:
- Article
Front-Line Vascular Access Devices in Acute Leukemias – Peripherally Inserted Central Catheter (PICC) Versus Traditional Central Venous Catheter (CVC): A Phase IV Randomized Trial (NCT02405728).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S396, doi. 10.1016/j.clml.2017.07.254
- By:
- Publication type:
- Article
Lenalidomide at the Dose of Twenty-five mg Every Other Day in Patients Affected by Multiple Myeloma and Renal Failure: A Real-life Experience.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e122, doi. 10.1016/j.clml.2017.03.221
- By:
- Publication type:
- Article
Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma.
- Published in:
- Case Reports in Hematology, 2016, p. 1, doi. 10.1155/2016/6745286
- By:
- Publication type:
- Article
Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 6, p. 885, doi. 10.1007/s11523-023-01001-4
- By:
- Publication type:
- Article